Chiesi reports significant international growth in 2015

Italian family-owned drugmaker Chiesi Farmaceutici closed 2015 on a high note by reporting annual turnover of 1,467 million euros ($1.79 billion), an increase of more than 9.4% over the previous year, and earnings before interest, taxes, depreciation and amortization (EBITDA) equal to 407 million euros (a year-on-year increase of over 9%).

The robust health of the company is mirrored in its investment in innovation and development, with R&D expenditure rising by over 28% in the 2014-2015 period, from 236 million euros to 300 million euros, or 20% of total sales. The group currently has 41 active research and development projects.

Chiesi remains committed to the Italian market, and 2015 saw significant investment in Italy with 35 million euros spent on expanding a state-of-the-art production plant in Parma to meet demand for one of the group’s most successful products.